Gene Therapy Research Institute Co. is focused on advancing gene therapy as a promising treatment for various medical conditions, particularly neurodegenerative diseases such as ALS and Parkinson's disease. The institute emphasizes the urgency of bringing effective gene therapy solutions to clinical practice, aiming to alleviate the suffering of patients who are currently awaiting fundamental treatments. Their commitment to this cause is driven by the belief in the therapeutic potential of gene therapy, which they view as a vital tool for improving patient outcomes and enhancing quality of life.

The company boasts a robust pipeline of over ten programs, leveraging a wide network to explore and develop innovative gene therapy solutions. Their lead programs are centered on high-potential treatments for ALS and Parkinson's disease, indicating a strategic focus on addressing significant unmet medical needs. By prioritizing research and development in gene therapy, the Gene Therapy Research Institute Co. aims to establish itself as a leader in the field, ultimately contributing to the global advancement of gene therapy applications in clinical settings.

Japan

Gene Therapy Research Institution Co., Ltd. is headquartered in Japan. Based on extensive research, the company is committed to providing safe and effective gene therapies for refractory diseases for which effective therapies have not yet been established. Focusing on Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, the company strives to find safer viral vectors and more effective genetic technologies to bring new treatment options to patients.

Central Nervous System (CNS)

Metabolic Diseases

Life Innovation Center 414 25-22, Kanagawa, Japan

Gene Therapy Research Institute Co.

Company Details